PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: marketing

EU Risk Management Plan for COVID-19 mRNA vaccine

ModernaTX, Inc. EU Risk Management Plan for Spikevax Page 1 EU Risk Management Plan for Spikevax (COVID-19mRNA vaccine ) Risk Management Plan (RMP) version to be assessed as part of this application: RMP version number: Data lock point for this RMP: 31 December 2021 Date of final sign off: 01 March 2022 Rationale for submitting an updated RMP: Update Spikevax indication to include individuals 6 years of age and older. Inclusion of mRNA-1273-P204 that evaluates the use of Spikevax in children 6 to < 12 years of age Summary of significant changes in this RMP: Compared to the previously approved COVID-19 vaccine Moderna European Union (EU) RMP version , this RMP version has been updated: To add paediatric information related to the new indication for individuals 6 years of age and older To update the Epidemiology of the Indication as of 31 December 2021 To update the clinical trial exposure data for mRNA-1273-P204 To add mRNA-1273-P204 as a Category 2 study in th

ModernaTX, Inc. EU Risk Management Plan for COVID-19 Vaccine Moderna Page 2 Part VI Summary of the risk management plan No changes Part VII Annexes Annex 2 – Milestones updates Annex 8 – updated to reflect the changes made from to

Tags:

  Milestone

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of EU Risk Management Plan for COVID-19 mRNA vaccine

Related search queries